KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Inventory (2018 - 2025)

Historic Change in Inventory for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q4 2025 value amounting to $13.9 million.

  • Alnylam Pharmaceuticals' Change in Inventory rose 173262.66% to $13.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$8.5 million, marking a year-over-year increase of 3764.53%. This contributed to the annual value of -$8.5 million for FY2025, which is 3764.53% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Change in Inventory is $13.9 million, which was up 173262.66% from -$5.0 million recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Change in Inventory peaked at $19.0 million during Q4 2022, and registered a low of -$12.0 million during Q4 2023.
  • Its 5-year average for Change in Inventory is $1.0 million, with a median of -$1.4 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' Change in Inventory was 173262.66% (2025), while the steepest drop was 2815000.0% (2025).
  • Over the past 5 years, Alnylam Pharmaceuticals' Change in Inventory (Quarter) stood at $10.8 million in 2021, then skyrocketed by 76.38% to $19.0 million in 2022, then tumbled by 163.18% to -$12.0 million in 2023, then skyrocketed by 92.92% to -$849000.0 in 2024, then soared by 1732.63% to $13.9 million in 2025.
  • Its last three reported values are $13.9 million in Q4 2025, -$5.0 million for Q3 2025, and -$11.1 million during Q2 2025.